Search results for "Immunization."

showing 10 items of 308 documents

B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP spe…

2015

The purpose of this study was to evaluate the adjuvant effect of the B subunits of cholera toxin (CT) and the thermolabile enterotoxin of Escherichia coli (LT) by the intrarectal route of immunization and compare them to the whole molecules CT and LT-R192G, a non toxic mutant of LT, using 2/6-VLP as an antigen, in mice. All molecules induced similar antigen specific antibody titers in serum and feces, whereas different T cell profiles were observed. CTB and LTB, conversely to CT and LT-R192G, did not induce detectable production of IL-2 by antigen specific T cells. Moreover, CTB, conversely to LT-R192G, CT and LTB, did not induce antigen specific CD4+CD25+Foxp3- and Foxp3+ T cells, thus sho…

RotavirusCholera Toxin[SDV]Life Sciences [q-bio]T cellmedicine.medical_treatmentBacterial ToxinsEnterotoxinBiologymedicine.disease_causeAntibodies ViralMicrobiologyAntibodiesMicrobiologyB subunitEnterotoxinsFecesMiceAntigenAdjuvants ImmunologicImmunologicAdministration RectalmedicineAnimalsViralAdjuvantsIL-2 receptorVaccines Virus-Like ParticleThermolabileB cellVaccinesIntrarectalEscherichia coli ProteinsCholera toxinRotavirus VaccinesLT-R192G3. Good healthVirus-Like ParticleInfectious Diseasesmedicine.anatomical_structureAdministrationAntibody FormationInterleukin-2Th17 CellsImmunizationRectalAdjuvantImmunologic MemoryMicrobial pathogenesis
researchProduct

Monitoring the rate of hospitalization before rotavirus immunization in Italy utilizing ICD9-CM regional databases

2009

BACKGROUND: Recently, two Rotavirus (RV) vaccines were licensed in Italy, rendering RV illness a vaccine preventable disease. To assess the RV hospitalization rate in Italy, a study focused on the Regional hospital discharge forms (HDD) databases was carried out. RESULTS: Regional HDD databases from Piemonte, Veneto, Friuli-Venezia-Giulia and Marche were analyzed. A total of 434,335 hospitalizations were counted in the study timeframe and 13,234 VE diagnoses (3% of hospitalizations) were collected. A total of 8546 RVE cases (2% of hospitalizations, 64% of all VE) were observed, of which 1.2% were primary diagnoses (PD) and 0.8% secondary diagnosis (SD). The RVE hospitalization peak (4.9%) w…

RotavirusPediatricsmedicine.medical_specialtyDatabases FactualSettore MED/17 - Malattie InfettiveSettore MED/42 - Igiene Generale e ApplicataImmunologymedicine.disease_causecomputer.software_genreimmunizationRotavirus InfectionsHospitalization rateEnteritisrotavirus; immunization; regional databasesRotavirusvaccineMedicineHumansICD9-CMGeneral Pharmacology Toxicology and PharmaceuticsenteritisdatabaserotaviruDatabasebusiness.industryData CollectionInfant NewbornInfantSecondary diagnosismedicine.diseasevaccinationregional databasesRotavirus; enteritis; vaccine; hospitalization; ICD9-CM; databaseVaccinationRegional hospitalImmunizationItalyChild PreschoolbusinesscomputerViral enteritishospitalization
researchProduct

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model.

2001

Abstract Background & Aims: The ability to induce cytotoxic T cells is considered an important feature of a candidate hepatitis C virus (HCV) vaccine. We used an oral immunization strategy with attenuated HCV-NS3–transformed Salmonella typhimurium to deliver DNA directly to the gut-associated lymphoid tissue. Methods: HLA-A2.1 transgenic mice were immunized once with transformed attenuated Salmonella . HCV-specific CD8 + T cells were analyzed in vitro as well as in vivo by challenge of mice with recombinant HCV-NS3 vaccinia virus. Results: Salmonella (10 8 colony-forming units; 20 μg plasmid DNA) induced cytotoxic and IFN-γ–producing CD8 + T cells specific for the immunodominant epitope NS3…

Salmonella typhimuriumViral Hepatitis VaccinesSalmonellavirusesAdministration OralMice TransgenicHepacivirusViral Nonstructural Proteinsmedicine.disease_causeMajor histocompatibility complexEpitopeVirusMicrobiologychemistry.chemical_compoundInterferon-gammaMiceInterferonHLA-A2 AntigenmedicineVaccines DNACytotoxic T cellAnimalsVaccines SyntheticHepatologybiologyGastroenterologyvirus diseasesbiochemical phenomena metabolism and nutritionVirologydigestive system diseaseschemistrybiology.proteinImmunizationVacciniaCD8medicine.drugT-Lymphocytes CytotoxicGastroenterology
researchProduct

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipien…

2009

The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly …

SerotypeAdultMaleHeptavalent Pneumococcal Conjugate VaccineAdolescentActive immunizationcomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesYoung Adultstomatognathic systemConjugate vaccineHeptavalent Pneumococcal Conjugate VaccinemedicineHumansTransplantation HomologousSeroconversionChildTransplantationGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPneumococcal vaccineMiddle AgedAntibodies BacterialAllogeneic stem cell transplantationVaccinationInfectious DiseasesStreptococcus pneumoniaePneumococcal vaccineImmunologyMolecular MedicineFemalebusinessPneumococcal infectionmedicine.drugStem Cell Transplantation
researchProduct

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vacc…

2010

13-valent pneumococcal conjugate vaccine (PCV13) was compared to PCV7 in infants administered 4 doses. For the 7 common serotypes, PCV13- and PCV7-elicited responses showed comparable percent responders achieving 0.35mug/mL IgG threshold (exception 6B, 77.5% versus 87.1%, respectively) and OPA titers of 1:8; IgGs were lower than PCV7 but functional responses were generally comparable. For the 6 additional serotypes, PCV13-elicited IgG and functional OPA responses were notably greater than PCV7. The toddler dose boosted immune responses. Vaccines were comparable with regard to safety. PCV13 should be as effective as PCV7 in preventing pneumococcal disease caused by the common serotypes and m…

SerotypeMaleHeptavalent Pneumococcal Conjugate Vaccinemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsPneumococcal Vaccinesstomatognathic systemDouble-Blind MethodGermanyStreptococcus pneumoniaemedicineHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ScheduleVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPneumococcal infectionsInfectious DiseasesImmunizationImmunoglobulin GImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Effectiveness of different vaccine formulations against vibriosis caused by Vibrio vulnificus serovar E (biotype 2) in European eels Anguilla anguilla

2001

Vibriosis due to Vibrio vulnificus serovar E (biotype 2) is one of the main causes of mortality in European eels cultured in Europe. The main objective of this study was to develop a vaccine and a vaccination procedure against this pathogen. With this aim, we tested several vaccine formulations (inactivated whole-cells with and without toxoids‹inactivated extracellular products‹from capsulated and uncapsulated strains, attenuated live vaccines and purified lipopolysaccharide [LPS]) on eels maintained under controlled laboratory conditions using different delivery routes (injection and immersion). To study the immune response we estimated antibody titers and bactericidal/bacteriostatic activ…

SerotypeQuality ControlVibrio vulnificus serovar E ; Vibrio vulnificus biotype 2 ; Eel vaccines ; Vibrio vaccines ; Vaccination by injection ; Vaccination by prolonged immersionImmunization SecondaryVibrio vulnificus biotype 2Eel vaccinesVibrio vulnificusAquacultureAquatic ScienceBiologyAntibodies Viral:CIENCIAS DE LA VIDA [UNESCO]MicrobiologyFish DiseasesVaccination by injectionAntigenVibrionaceaeImmunityAntibody SpecificityUNESCO::CIENCIAS DE LA VIDAAnimalsUNESCO::CIENCIAS DE LA VIDA::Biología animal (Zoología)Vibrio vaccinesPathogenEcology Evolution Behavior and SystematicsVaccination by prolonged immersionSkinVibrio:CIENCIAS DE LA VIDA::Biología animal (Zoología) [UNESCO]VaccinationAntibody titerbiology.organism_classificationAnguillaVirologyVaccinationEuropeVibrio vulnificus serovar EVibrio InfectionsBacterial Vaccines
researchProduct

Community-based Immunization Strategies for Epidemic Control

2014

Understanding the epidemic dynamics, and finding out efficient techniques to control it, is a challenging issue. A lot of research has been done on targeted immunization strategies, exploiting various global network topological properties. However, in practice, information about the global structure of the contact network may not be available. Therefore, immunization strategies that can deal with a limited knowledge of the network structure are required. In this paper, we propose targeted immunization strategies that require information only at the community level. Results of our investigations on the SIR epidemiological model, using a realistic synthetic benchmark with controlled community…

Social and Information Networks (cs.SI)FOS: Computer and information sciencesPhysics - Physics and SocietyComputer scienceControl (management)Community structureFOS: Physical sciencesComputer Science - Social and Information NetworksPhysics and Society (physics.soc-ph)Immunization (finance)Targeted immunization strategiesRisk analysis (engineering)Global networkBenchmark (computing)CentralityEpidemic control
researchProduct

Immunoassays for trifloxystrobin analysis. Part I. Rational design of regioisomeric haptens and production of monoclonal antibodies

2014

Trifloxystrobin is one of the main active principles belonging to the strobilurin family of crop protection compounds. In this article, the synthesis of a battery of regioisomeric functionalized derivatives of trifloxystrobin is described. The same aliphatic linear carboxylated chain was introduced as spacer arm in all of the synthesized haptens, but it was located at different positions of the parent molecule. N,N′-Disuccinimidyl carbonate was employed for hapten activation, so the resulting N-hydroxysuccinimyl ester could be readily purified and efficiently coupled to proteins. After immunization and hybridoma generation, a collection of 20 mouse monoclonal antibodies from different immun…

Stereochemistrymedicine.drug_classFungicideEnzyme-Linked Immunosorbent Assaychemical and pharmacologic phenomenaAcetatesMonoclonal antibodyAnalytical ChemistryMiceIsomerismRegioisomeric haptensmedicineStrobilurinAnimalsImmune responseImmunoassayMolecular StructureChemistryRational designAntibodies MonoclonalGeneral MedicineDerivatization siteStrobilurinsFungicides IndustrialActive esterStrobilurinMethacrylatesImmunizationIminesSelectivityHaptenHaptensFood Science
researchProduct

Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4’-deoxy-4’-fluoro-Thomsen–Friedenreich epi…

2015

The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4’F-TF-MUC1-TTox conjugate resulted in strong im…

Synthetic vaccinemedicine.medical_treatmentMUC1Full Research PaperEpitopelcsh:QD241-441Immune systemCancer immunotherapylcsh:Organic chemistryConjugate vaccinemedicineskin and connective tissue diseaseslcsh:Scienceneoplasmsfluorinated carbohydratescancer immunotherapyChemistryImmunogenicityOrganic ChemistryTACAdigestive system diseasesglycoconjugatesChemistryImmunizationImmunologyCancer researchlcsh:QConjugateBeilstein Journal of Organic Chemistry
researchProduct

T cell avidity determines the level of CTL activation

2004

To investigate the influence of avidity on T cell activation in vitro and in vivo, we analyzed T cells from St40 and St42 mice, which express the same transgenic TCR specific for an E1a-derived epitope of adenovirus type 5 with different expression levels and therefore different avidities. Splenocytes from both strains showed comparable cytolytic activities and required identical peptide concentrations for efficient target cell lysis and up-regulation of activation markers. However, the kinetics of CD25 up-regulation were strikingly different: whereas the majority of the high-avidity St42 T cells up-regulated the IL-2Ralpha chain within a few hours, low-avidity St40 T cells expressed only 5…

T cellImmunologyReceptors Antigen T-CellMice Transgenicchemical and pharmacologic phenomenaStreptamerBiologyLymphocyte ActivationAdenoviridaeMiceInterleukin 21medicineAnimalsImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellCells CulturedCD28Receptors Interleukin-2Natural killer T cellAdoptive TransferMolecular biologymedicine.anatomical_structureCytokinesImmunizationBiomarkersCell DivisionSpleenT-Lymphocytes CytotoxicEuropean Journal of Immunology
researchProduct